Gilead earnings beat forecasts, but acquisition charges deepen its annual loss outlook
Earnings results
- EPS beat +17.5%
Actual: $2.55 · Cons.: $2.17 (non-GAAP diluted EPS)
- Revenue beat +6.3%
Actual: $8.3B · Cons.: $7.81B (reported total revenue)
- Guidance
2026 product sales raised to $31.0–$31.3 billion from $30.1–$30.4 billion; adjusted loss forecast widened
Earnings and the stock move
Gilead’s newly released quarter showed HIV demand and pricing supporting higher product sales and an increased annual sales forecast. That can strengthen cash generation, but the widened annual loss outlook shows how acquisition-related research costs absorb the benefit. Some quarterly sales growth also reflected favorable inventory changes, which may not repeat.
Q3 2026 ended September 30 earnings recap
Gilead rose 1.4% after hours on October 29 after quarterly earnings beat forecasts and its product-sales outlook increased. A deeper annual loss forecast adds a caution to the stronger sales picture.
- Adjusted earnings per share, or profit per share, were $2.55 versus the $2.17 forecast, a 17.5% beat. GAAP earnings were $1.94 per share, down from $2.43 a year earlier.
- Total revenue reached $8.3 billion versus the $7.81 billion forecast, a 6.3% beat. Product sales grew 13%, while total revenue grew 7% because royalty and other revenue fell.
- HIV sales rose 18% to $6.25 billion, helped by prevention demand, higher realized prices and inventory changes. Investors should watch how much growth continues as those inventory effects fade.
- Gilead raised annual product-sales guidance to $31–$31.3 billion from $30.1–$30.4 billion. This forecast covers product sales rather than total revenue.
- The annual adjusted loss forecast widened to $0.85–$1.2 per share from $0.3–$0.65. Acquisition-related research costs remain included in this adjusted measure, so a strong quarter does not imply an annual profit.
- Quarterly operating cash flow reached $5.04 billion. Cancer treatment Trodelvy grew strongly, but cell-therapy sales fell 18% amid competition, showing that growth remains uneven.
Watch whether HIV demand and new medicines sustain sales growth while acquisition spending produces useful treatments. The October 29 charts show the regular close before results; the next regular session will test the initial reaction.
Financials and technicals
Charts through Oct 29, 2026. The session move above may reflect later news.
Technical setup and risks
The completed October 29 charts precede the earnings release. Holding above the regular close would support the initial after-close reaction; falling back below it would weaken that signal. The next regular session will provide a fuller test of buying interest.
After-hours move is measured versus the same-day regular close AI-assisted research with source and calculation checks. Prices may be delayed. Technical charts use the stated completed session, which can precede the quoted intraday move. Educational information; investing involves risk.